Pfizer stock gained on multiple developments announced on February 3-6, 2026. The company reported positive Phase 2b results from its VESPER-3 study of PF-08653944, a monthly injectable GLP-1 receptor agonist for obesity treatment, showing statistically significant placebo-adjusted weight loss of 12.30%. Pfizer plans to launch an extensive Phase 3 development program with more than 20 pivotal studies and multiple Phase 3 trials in 2026. Additionally, the FDA granted Priority Review for HYMPAVZI (marstacimab) supplemental application to expand treatment to hemophilia A or B patients ages 6 and older with inhibitors and pediatric patients ages 6-11 without inhibitors. Pfizer also launched a cost savings program through TrumpRx offering over 30 medicines at discounted prices under a Most Favored Nation agreement with the U.S. government.
Read full analysisPfizer stock gained on multiple developments announced on February 3-6, 2026. The company reported positive Phase 2b results from its VESPER-3 study of PF-08653944, a monthly injectable GLP-1 receptor agonist for obesity treatment, showing statistically significant placebo-adjusted weight loss of 12.30%. Pfizer plans to launch an extensive Phase 3 development program with more than 20 pivotal studies and multiple Phase 3 trials in 2026. Additionally, the FDA granted Priority Review for HYMPAVZI (marstacimab) supplemental application to expand treatment to hemophilia A or B patients ages 6 and older with inhibitors and pediatric patients ages 6-11 without inhibitors. Pfizer also launched a cost savings program through TrumpRx offering over 30 medicines at discounted prices under a Most Favored Nation agreement with the U.S. government.
Pfizer Inc (PFE) is a publicly traded company in the Healthcare sector.